Skip to main content

Advertisement

SpringerLink
Log in

Dualistic Classification of Epithelial Ovarian Cancer: Surgical and Survival Outcomes in a Large Retrospective Series

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Ovarian cancers have been recently categorized into types I and II according to a dualistic model of tumorigenesis. Data on the correlation between this classification and clinical outcome are still scarce and controversial.

Methods

A retrospective analysis of patients with ovarian cancer treated from 1998 to 2013 and operated by the same surgeon was conducted. Patients were classified into two groups: type I (125 patients), including low-grade serous, mucinous, endometrioid, and clear cell tumors; and type II (286 patients), including high-grade serous tumors, unspecified adenocarcinomas, and undifferentiated carcinomas.

Results

Type II patients had a significantly higher incidence of advanced disease than type I (88.4 vs. 65.6 %, P = 0.0001) and required more aggressive surgical procedures. Rates of optimal tumor debulking were almost similar between groups (92.6 vs. 91.7 %, type I vs. II, P = NS). After a median follow-up of 41 months, 207 patients (50.4 %) were alive and 204 (49.6 %) were dead; 79 type I patients (63.8 %) and 237 type II patients (82.7 %) experienced relapse (P = 0.02). Progression-free survival was significantly different between groups: 25 months for type I vs. 17 months for type II (P = 0.023). Overall survival was not significantly different between groups, with a median overall survival of 75 months for type I vs. 62 months for type II (P = 0.116).

Conclusions

The dualistic histotype-based classification into types I and II of ovarian cancer does not seem to correlate with prognosis. Different molecular characteristics of type I and II tumors may have therapeutic implications and should be deeply investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Seidman JD, Yemelyanova A, Cosin JA, Smith A, Kurman RJ. Survival rates for International Federation of Gynecology and Obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int J Gynecol Cancer. 2012;22:36–71.

    Article  PubMed  Google Scholar 

  2. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–8.

    Article  Google Scholar 

  3. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol. 2011;42:918–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433–43.

    Article  PubMed Central  PubMed  Google Scholar 

  5. McAlpine JN, Porter H, Kobel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25:740–50.

    Article  CAS  PubMed  Google Scholar 

  6. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006; Suppl 1:S161–S192.

    Article  Google Scholar 

  7. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19:7–15.

    Article  CAS  PubMed  Google Scholar 

  8. BenedettiPanici P, DeVivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14:1136–42.

    Article  PubMed  Google Scholar 

  9. Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer. 2011;105:1818–24.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Bamias A, Sotiropoulou M, Zagouri F, et al. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. Eur J Cancer. 2012;48:1476–83.

    Article  CAS  PubMed  Google Scholar 

  11. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267–82.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(Suppl 2):19–32.

    Article  Google Scholar 

  13. Chen X, Zhang J, Cheng W, et al. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23:815–22.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Kajiyama H, Shibata K, Mizuno M, et al. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer. 2012;22:801–6.

    Article  PubMed  Google Scholar 

  15. Kajiyama H, Shibata K, Mizuno M, et al. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type? Int J Gynecol Cancer. 2012;22:394–9.

    Article  PubMed  Google Scholar 

  16. Kajiyama H, Mizuno M, Shibata K, Kawai M, Nagasaka T, Kikkawa F. Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer. Int J Clin Oncol. 2014; 19(1):121–126

    Article  PubMed  Google Scholar 

  17. Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114:48–52.

    Article  PubMed  Google Scholar 

  18. Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;1;8:252.

    Article  Google Scholar 

  19. Vergote I, Tropé CG, Amant F, et al European Organization for Research and Treatment of Cancer–Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  CAS  PubMed  Google Scholar 

  20. Chang SJ, Bristow RE. Evolution of surgical treatment paradigmsfor advanced-stage ovarian cancer: redefining “optimal” residual disease. Gynecol Oncol. 2012;125:483–92.

    Article  PubMed  Google Scholar 

Download references

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gynecological and Obstetrical Sciences and Urological Sciences, Sapienza University of Rome, Rome, Italy

    Pierluigi Benedetti Panici MD, Claudia Marchetti MD, Laura Salerno MD, Angela Musella MD, Laura Vertechy MD, Innocenza Palaia MD, Giorgia Perniola MD, Ilary Ruscito MD, Terenzio Boni MD & Ludovico Muzii MD

  2. Department of Gynecology, Campus Bio-Medico University of Rome, Rome, Italy

    Roberto Angioli MD

Authors
  1. Pierluigi Benedetti Panici MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Marchetti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura Salerno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angela Musella MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Vertechy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Innocenza Palaia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giorgia Perniola MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ilary Ruscito MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Terenzio Boni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Roberto Angioli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ludovico Muzii MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia Marchetti MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panici, P.B., Marchetti, C., Salerno, L. et al. Dualistic Classification of Epithelial Ovarian Cancer: Surgical and Survival Outcomes in a Large Retrospective Series. Ann Surg Oncol 21, 3036–3041 (2014). https://doi.org/10.1245/s10434-014-3714-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-3714-6

Keywords

Search

Navigation